Critical Illness, Hematopoetic Stem Cell Transplantation, Transplant Complication, Ventilated Patients
Conditions
Keywords
hematopoietic cell transplantation, critical illness, management, prognosis, transplant complication
Brief summary
This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation. Patients who are admitted to the intensive care unit after undergoing hematopoietic cell transplantation at the participating medical centers will be enrolled in this study. The clinical characteristics, laboratory profiles, managements, and clinical outcomes will be prospectively collected.
Interventions
None listed
Sponsors
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
Xinqiao hospital of the third military medical university
First Affiliated Hospital of Zhejiang University
First Affiliated Hospital of Harbin Medical University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients who underwent hematopoietic cell transplantation at any of the participating medical centers. * Patients who are admitted to ICU for the management of critical illness following hematopoietic cell transplantation.
Exclusion criteria
* Admitted to ICU for a reason other than critical illness (e.g., routine postoperative monitoring) and discharged within 2 days of ICU admission. * Unavailable in-ICU clinical outcomes or absent key baseline characteristics. * Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Before ICU discharge; within 6 months after ICU discharge; and within 1 year after ICU discharge. | Overall survival after admission to the intensive care unit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relapse | At ICU admission and within 1 year of ICU discharge. | Disease relapse or progression at or after ICU admission. |
| Transplant complication | At ICU admission and within 1 year of ICU discharge. | Hematopoietic-cell-transplantation-associated complications at or after ICU admission. |
| Non-relapse mortality | Before ICU discharge; within 6 months after ICU discharge; and within 1 year after ICU discharge. | Non-relapse mortality after ICU admission. |
| Organ support therapy | At ICU admission and within 1 year after ICU discharge. | The use of organ support therapy at or after ICU admission. |
| Long-term survival data | Up to 5 years after ICU discharge. | Overall survival, non-relapse mortality, and transplant-related mortality during long-term follow-up after ICU discharge. |
| Organ failure | At ICU admission and within 1 year of ICU discharge. | Organ failure occurring at or after ICU admission. |
Countries
China
Contacts
Primary ContactXiao Hui Zhang, MD
Backup ContactPeng Zhao, MD
Outcome results
None listed